AorticLab's FLOWer™ embolic protection device has received full clearance following the Unified Patent Court's clear dismissal of Emboline's infringement claims regarding European Patent EP 2129425, ensuring continued patient access to its innovative technology COLLERETTO GIACOSA, Italy, Jan. 20, 2026 /PRNewswire/ -- AorticLab S.r.l. today announce sits clear victory before the Court...

AorticLab™ is pleased to announce the successful achievement of CE certification for FLOWer™, an innovative transcatether embolic protection device (EPD) indicated for the cerebral and systemic protection of patients undergoing transcatheter aortic valve replacement (TAVI) procedures. The CE certification of FLOWer, a Class III medical...

AorticLab will attend the upcoming European HealthTech CEO Forum 2020, 18th February 2020, Hilton Zurich Airport Hotel, Switzerland. Presentation Time & Location: 10.40 – Track B – Room Berne – on 18th of February https://www.sachsforum.com/ehtf-about.html...

San Francisco, CA. 25 September 2019, Dr. Filippo Scalise presented the AorticLab devices and development project at TCT innovator day at the Moscone Center. Speech title: Innovative protected transcatheter aortic valve calcium debridement system (AorticLab) https://www.tctmd.com/slide/innovative-protected-transcatheter-aortic-valve-calcium-debridement-system-aorticlab...